Stocks to Track: Whiting Petroleum Corporation (NYSE:WLL) , Arrowhead Research Corporation (NASDAQ:ARWR)

On 11/30/2016, Shares of Whiting Petroleum Corporation (NYSE:WLL) closed at $12.22 in last trading day. After noting the initial trading entry at $10.39, it reached to a day’s high of $12.39 and moved to a day’s low of $10.31. The recent daily volume was 81.67 million as contrast to it’s an average volume of 23.66 million.

Technical Indicators:

The last close of the Whiting Petroleum Corporation stock reflects that it traded up +38.03% from its 50-day moving average of $8.85. The stock traded above +35.04% to its 200-day MA of $9.05. Furthermore, it moved lower -26.47% from its 52-week high of $16.62 and +264.78% up from $3.35, which is 52-week low of the stock.

The 36 analysts offering 12-month price forecasts for Whiting Petroleum Corp have a median target of 11.00, with a high estimate of 20.00 and a low estimate of 6.90. The median estimate represents a -9.98% decrease from the last price of 12.22., according to CNN MONEY.

The current consensus among 38 polled investment analysts is to hold stock in Whiting Petroleum Corp. This rating has held steady since November, when it was unchanged from a hold rating.

Arrowhead Research Corporation (NASDAQ:ARWR) finalized the last transaction at value of $1.44, with a daily change of -67.20% or -2.95 points. It has a market cap of $ 87.48M.

Technical Indicators:

As of last trade close, the stock is trading  downside -82.48% from its one year high of $8.22 and moved -53.09% downward from $3.07, which is one year low of the stock.

The stock traded below -74.48% from its 50-day moving average of $5.64. Furthermore, the stock moved down -76.39% to its 200-day MA of $ 6.10.

According to CNN MONEY data, The 6 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 5.00. The median estimate represents a +663.89% increase from the last price of 1.44.

The current consensus among 6 polled investment analysts is to buy stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a buy rating.

Leave a Reply

Your email address will not be published. Required fields are marked *